ClinicalTrials.gg
Sign In
Enrolling by invitationNCT06469814GRASP-HFUpdated Aug 20, 2026

Snapshot Study on Patients With Heart Failure

An observational study in Heart Failure, sponsored by European Society of Cardiology. Enrolling by invitation at 63 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by European Society of Cardiology · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to provide a better understanding of medical practice for heart failure management based on real-world data, collected both across Europe and the rest of the world, using robust methodology and representativeness within each country.

Standard management of patients will be the diagnostic and therapeutic interventions routinely performed in each center for patients presenting with signs and symptoms of chronic/acute heart failure.

Read the detailed description

Information collected by the GRASP-HF study assesses adherence to the ESC HF Guidelines focusing on Quality Indicators, in both chronic and acute HF.

For that reason, the GRASP-HF snapshot study is evolving in parallel with the long-term Heart Failure Association initiative - ICARe-HF: the Improving Care through Accreditation and Recognition in Heart Failure (ICARe-HF) programme. ICARe-HF is an international accreditation programme for heart failure centres which is about improving patient outcomes by raising standards in care facilities and recognising those that apply best practices. The GRASP-HF snapshot study serves to verify the performance of individual centres through data collection of real-world patient data.

02

Conditions studied

  • Heart Failure

Browse trials for

03

In context

Heart Failure

6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

This study's planned enrollment of 4,000 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

European Society of Cardiology is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is all consenting patients seen in the outpatient clinic for chronic HF and all consenting patients admitted for acute HF in the study center as their standard medical care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients with chronic or acute Heart Failure (HF), regardless of , either:

  • Outpatient with chronic HF (including first-time diagnosis), according to the clinical judgment.

OR

  • Patients admitted to hospital or presenting to Emergency Department or Acute out-patient care for acute HF for whom an IV (diuretics, inotropes, vasodilators) or mechanical therapy for HF (mechanical circulatory support) is administered.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Patients unwilling to consent (or patient's legally authorized representative unwilling to consent, if the patient is unable to consent).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Patients with chronic heart failure
  • Patients with acute heart failure
06

What researchers measure

Primary outcomes

  1. Adherence to ESC Guidelines in Heart Failure 2021

    Full adherence to guidelines for heart failure management

    Time frame: 12 months per site

07

Study locations

63 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jul 2025, 10 months.

Of 793 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's 10 months is below that.

Counting every sponsor, half of 975 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jun 24, 2024
StartActual
Sep 27, 2024
Primary completionActual
Jul 30, 2025
CompletionEst.
Jul 2029
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06469814
Lead sponsor
European Society of Cardiology
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Sep 27, 2024
Primary completion
Jul 30, 2025
Completion
Jul 2029 (estimated)
Last update
Aug 20, 2026

Study contacts

Ovidiu Chioncel
study chair · Institute for Cardiovascular Diseases C.C. Iliescu, Bucaresti, Romania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Failure →

Other studies from this sponsor

European Society of Cardiology

Start the discussion